Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo

NCT01367314 is registered in ClinicalTrials.gov with NovaBay Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01367314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01367314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
December 31, 2010
Enrollment
129 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

impetigo